trial

A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia

NCTId NCT00686140
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 200 (actual)
Sponsored by Beijing HuiLongGuan Hospital
Primary completion 2007-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
200 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2006-06
Primary completion
2007-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
celecoxib

Sponsors

Beijing HuiLongGuan HospitalLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Lian Y Cao, M.D.Study Chair

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
200
Phase
NA
Primary Completion Date
2007-12
Status
COMPLETED
relationships
The graph out of here
drug
celecoxib
drug
lead_sponsor
Beijing HuiLongGuan Hospital
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Lian Y Cao, M.D.
person